Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia
Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia
复制标题
DOI：
10.1046/j.1365-2141.2003.04394.x
复制
发表时间：
2003-07-01
影响因子：
6.5
通讯作者：
Van Dongen, J
中科院分区：
文献类型：
--
作者：
Goulden, N;Bader, P;Van Dongen, J
异基因造血干细胞移植（SCT）是治疗儿童急性淋巴细胞白血病（ALL）的一种有效方法。对不必要的毒性和费用的担忧意味着SCT目前主要用于无法通过化疗治愈的儿童。毫不奇怪，许多这样的孩子也失败了SCT。回顾性研究表明，对SCT前微小残留病（MRD）的单一分析可确定复发风险最高的患者。现在，呼吁将标准化MRD检测普遍纳入SCT方案是适当的，下一步是最大限度地发挥这项技术在ALL中的临床影响。
Allogeneic stem cell transplantation (SCT) is a highly effective therapy for childhood acute lymphoblastic leukaemia (ALL). Concerns about unnecessary toxicity and expense mean that SCT is currently largely reserved for children who cannot be cured with chemotherapy. Not surprisingly, many such children also fail SCT. Retrospective studies have shown that a single analysis of minimal residual disease (MRD) pre-SCT identified those at highest risk of relapse. It is now appropriate to call for the universal incorporation of standardized MRD testing into SCT protocols as the next step to maximize the clinical impact of this technology in ALL.